Placebo to ISL
Sponsors
Merck Sharp & Dohme LLC, MSD Pty Ltd.
Conditions
HIV Preexposure ProphylaxisHIV-1 InfectionHIV-IHIV/AIDSHuman Immunodeficiency Virus Type 1Prophylaxis
Phase 2
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
CompletedNCT04564547
Start: 2021-03-09End: 2025-01-30Updated: 2026-01-26
A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-Daily
CompletedCTIS2024-511041-19-00
Start: 2021-04-06End: 2025-01-28Target: 48Updated: 2025-01-29
Phase 3
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)
CompletedNCT04233216
Start: 2020-03-18End: 2023-11-01Updated: 2024-12-27
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
TerminatedNCT04644029
Start: 2021-02-24End: 2024-06-11Updated: 2026-02-04
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
TerminatedNCT04652700
Start: 2021-03-15End: 2023-08-04Updated: 2025-01-13
MK8591-024: Oral ISL QM as PrEP in MSM and TGW at High Risk for HIV-1 Infection
Active, not recruitingPACTR202109759050023
Start: 2021-06-01Target: 1500Updated: 2026-01-27